Dynamic contrast enhanced MRI as a predictor of vascular-targeted photodynamic focal ablation therapy outcome in prostate cancer post-failed external beam radiation therapy - Abstract

INTRODUCTION: Photodynamic therapy (PDT) can be employed as a focal therapy for prostate cancer.

Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) can potentially help identify tumour recurrence after failed external-beam radiotherapy (EBRT). The purpose of this study was to determine the ability of DCE-MRI to predict early response to PDT salvage treatment.

METHODS: Patients with post-EBRT prostate cancer recurrence were prospectively enrolled into a Phase I/II trial of PDT using WST09. A 15-patient subgroup of this cohort undergoing 1.5T DCE-MRI at baseline and 1-week post-PDT was retrospectively analyzed. The reference standard was prostate biopsy obtained 6 months post-PDT. Analysis was performed on a patient-by-patient basis, by prostate gland halves, and by prostate sextants.

RESULTS: Biopsy 6 months post-PDT identified cancer in 10/15 patients (66.7%), and in 24/90 sextants (26.7%). Residual cancer was identified in 22/37 sextants (59.5%) identified as being involved at baseline. DCE-MRI at 1 week correctly predicted recurrent disease with a sensitivity of 100% (10/10), specificity of 60% (3/5), positive predictive value of 83.3% (10/12), negative predictive value of 100% (3/3), and an overall accuracy of 86.7%, (13/15). When analysis was performed on prostate halves, the sensitivity and negative predictive value remained at 100%, with an improvement in specificity to 88.2% (15/17). The overall accuracy of DCE-MRI was similar regardless of analysis method: 86.7% on a patient-by-patient basis, 86.7% by prostate half and 83.3% by sextant. Changes in prostate-specific antigen (PSA) did not correlate to response.

CONCLUSION: DCE-MRI shows promise as a tool to predict successful outcome when performed 1 week post-PDT and could potentially be used to inform the need for re-treatment at an early time-point.

Written by:
Barrett T, Davidson SR, Wilson BC, Weersink RA, Trachtenberg J, Haider MA.   Are you the author?
Department of Medical Imaging, University Health Network, Toronto, ON; Division of Biophysics and Bioimaging, Ontario Cancer Institute, University Health Network, Toronto, ON; Laboratory for Applied Biophysics, Ontario Cancer Institute, University Health Network, Toronto, ON; Division of Urology, Department of Surgical Oncology, University Health Network, Toronto, ON; Department of Medical Imaging, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, ON.

Reference: Can Urol Assoc J. 2014 Sep;8(9-10):E708-14.
doi: 10.5489/cuaj.2176


PubMed Abstract
PMID: 25408811

UroToday.com Prostate Cancer Section

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe